Needham analyst Mike Matson lowered the price target on Neogenomics (NASDAQ: NEO) to $18.00 (from $19.00) while maintaining a Buy ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE